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Mood Disorders and Substance Use Disorder: A Complex Comorbidity
Mood disorders, including depression and bipolar disorders, are the most common psychi-
atric comorbidities among patients with substance use disorders. Treating patients’ co-
occurring mood disorders may reduce their substance craving and taking and enhance their
overall outcomes. A methodical, staged screening and assessment can ease the diagnostic
challenge of distinguishing symptoms of affective disorders from manifestations of sub-
stance intoxication and withdrawal. Treatment should maximize the use of psychotherapeu-
tic interventions and give first consideration to medications proven effective in the context of
co-occurring substance abuse. Expanded communication and collaboration between sub-
stance abuse and mental health providers is crucial to improving outcomes for patients with
these complex, difficult co-occurring disorders.
M
ood or affective disorders, as defined by the Diagnostic and Statistical
Manual of Mental Disorders (Fourth Edition), are classified as depressive
or bipolar (Table 1). During the past decade, research results and clinical expe-
rience have converged in the recognition that these psychiatric illnesses com-
monly co-occur with substance use disorders (SUDs) and that the combination
has adverse clinical consequences. Mood and SUD comorbidity downgrades the
clinical course, treatment outcome, and prognosis for each problem. Theoretically,
the converse is also likely to be true: Successful alleviation of one condition should
facilitate recovery from the other. Some evidence indicates that treating a comor-
bid affective disorder can decrease substance abuse and craving (Cornelius et al.,
1997).
Researchers and clinicians have begun to develop treatment approaches that
address both disorders simultaneously, with early indications of efficacy. This arti-
cle explores the prevalence and relationship of co-occurring mood disorders
and SUDs, describes a methodical approach to assessment, and reviews evidence-
based psychotherapeutic and pharmacotherapeutic treatments.
EPIDEMIOLOGICAL RELATIONSHIPS
Two epidemiological studies have examined the prevalence of psychiatric and
substance use disorders by conducting diagnostic interview surveys in represen-
tative community samples of adults: the National Institute of Mental Health
Epidemiologic Catchment Area (ECA) Study (Regier et al., 1990) conducted in14 • SCIENCE & PRACTICE PERSPECTIVES—DECEMBER 2005
lence rates is the complexity of diagnostic issues at the
interface of mood disorders and SUDs. For exam-
ple, because abstinence from drugs can temporarily
depress mood, a patient who is evaluated while in with-
drawal may be misdiagnosed as suffering from a mood
disorder. Clinicians may reach different conclu-
sions, depending on when they conduct assessments
relative to the patient’s entry into treatment.
WHY ARE THESE COMORBIDITIES SO
COMMON?
The major mood disorders and their key clinical
features can be found in Table 1. Several theories have
been proposed to explain the high co-occurrence of
substance abuse and mood disorders. In general, they
fall into three categories. 
Disorder Fostering Disorder
One theory proposes that the pathological effects of
a mood disorder or SUD may increase risk for the
other. For example, mood disorders may motivate
individuals to resort to drugs and alcohol to cope with
their negative affective states. Such an explanation
would jibe with clinicians’ everyday experience of indi-
viduals with SUDs saying they use drugs and alcohol
to combat unwanted moods. The substances may ini-
tially minimize or moderate the mood symptoms, but
withdrawal and chronic abuse typically exacerbate
mood degradation, leading to increasing abuse and
ultimately dependence.
The self-medication explanation implies that
individuals will tend to select drugs that alleviate their
specific psychiatric symptoms. For example, some psy-
chologists suggest that people with uncontrollable
feelings of rage and aggression may choose opiates for
these drugs’ mellowing effects, while people who are
depressed may take cocaine because it exhilarates and
energizes them. Studies showing such associations
between abusers’ drugs of choice and their psychiatric
diagnoses or symptoms would strengthen the evidence
for the self-medication model, but to date few have
been published. 
While the self-medication model suggests that
mood disorders increase the risk of substance abuse,
the converse is also possible. Chronic substance abuse
sometimes “unmasks” bipolar or other mood disor-
ders—that is, triggers an increase in symptom sever-
ity from a subclinical to a clinically significant level.
This appears to occur because in genetically vulnera-
the early 1980s and the National Comorbidity Survey
(NCS) conducted in 1991 (Kessler et al., 1994). Both
provided striking documentation that mood disor-
ders increase the risk of SUD. 
In the ECA Study, the lifetime prevalence rate
for any non-SUD mental disorder was estimated to
be 22.5 percent, compared with 13.5 percent for alco-
hol abuse/dependence and 6.1 percent for other drug
abuse/dependence (Regier et al., 1990). Among indi-
viduals with a mood disorder, 32 percent had a co-
occurring SUD. Of individuals with lifetime major
depression, 16.5 percent had an alcohol use disorder
and 18 percent had a drug use disorder. SUDs were
particularly common among individuals with bipo-
lar disorder—56 percent had a lifetime SUD.
In the NCS, the lifetime prevalence estimate for
any mental disorder was 48 percent (Kessler et al., 1997).
The estimate for alcohol dependence was 14.1 percent,
and for drug dependence 7.5 percent. The lifetime
prevalence rate for any mood disorder was 19.3 per-
cent. Compared with individuals with no mood dis-
orders, those with depression were approximately twice
as likely, and those with bipolar disorder approximately
seven times as likely, to have an SUD. (The ECA study
also documented a high rate of co-occurrence of SUD,
mood, and anxiety disorders; while anxiety disorders
are clinically common and important, they are a sepa-
rate category of illness and discussion of them is beyond
the scope of this paper.)
Studies of individuals seeking treatment have
resulted in variable estimates of the comorbidity of
mood disorders and SUDs.  Among those seeking
treatment for alcohol dependence, an estimated 
20 to 67 percent had experienced depression and 6 to
8 percent had experienced a bipolar disorder at some
time in their lives (Brady, Myrick, and Sonne, 1998).
In samples of cocaine-dependent individuals, the cor-
responding estimates have ranged between 30 and 40
percent and between 10 and 30 percent. Rounsaville
and colleagues (1991), after assessing 298 cocaine
abusers seeking treatment, reported that 44.3 percent
had a current mood disorder and 61 percent had a
history of mood disorders; 30.5 percent had had at
least one episode of major depression and 11.1 per-
cent at least one episode of mania or hypomania.
Bipolar disorder appears to be more prevalent among
cocaine-dependent individuals than alcohol-
dependent individuals (Sonne and Brady, 1999).
One reason for the differences in reported preva-
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CATEGORY
Depressive Disorders
(no history of manic,*
mixed manic,** or
hypomanic***
episodes)
Bipolar Disorders
(manic,* mixed,** or
hypomanic***
episodes plus major
depressive episodes)
Substance-Induced
Mood Disorder
DISORDER TYPE
Major depressive 
disorder
Dysthymic disorder
Bipolar I
Bipolar II
Cyclothymia
KEY FEATURES
2-week duration, with
depressed mood/loss
of interest
Chronic, less severe
than MDD; 2-year
duration
One or more manic/
mixed and depressive
episode
One or more depres-
sive and at least one
hypomanic episode
Chronic/less severe
form of bipolar dis-
order; 2-year duration,
with multiple periods
of hypomania/depres-
sion
Prominent and persist-
ent mood disturbance,
direct physiologic con-
sequence of substance
use 
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ble individuals, the drugs exacerbate pathophysio-
logical changes in neurotransmitter systems or signal-
ing pathways that already are abnormal and underlie
the mood disorder (Markou, Kosten, and Koob, 1998).
Overlapping Neurobiological Pathways
Another proposed explanation for the high comor-
bidity rate of mood disorders with SUDs involves “kin-
dling.” The term, usually associated with epilepsy,
refers to the concept that repeated disruptions, such
as occur during seizures, sensitize brain cells. The more
sensitized the neurons become, the less it takes to dis-
rupt them, which is why in untreated epilepsy, seizures
tend to become more frequent and severe over time.
Both alcohol and cocaine sensitize neurons, and this
increased sensitivity may contribute to the typical pro-
gression from occasional to increasingly frequent and
intense use of these substances. Mood disorders often
follow a similar course of increasingly distressing symp-
tomatic episodes separated by progressively shorter
periods of remission, suggesting that they too may
intensify via a kindling process (Post, Rubinow, and
Ballenger, 1984). The kindling explanation for comor-
bidity, then, holds that in vulnerable individuals, an
underlying neurobiological tendency to sensitization
may promote both drug dependence and mood dis-
orders.
Underlying Genetic Factors
Research has definitively shown that both substance
abuse and mood disorders have genetic risk factors.
In addition, families with substance abusers are more
likely than those without to also have members with
mood disorders, and vice versa. These facts raise the
possibility that some gene variants may contribute to
the risk for both types of illness. A person’s genes might:
• make him or her vulnerable to mood disorders, which
he or she might then try to self-medicate, as dis-
cussed above;
• shape the brain so that it responds to initial drug
exposures in ways that promote chronic substance
abuse, with the drugs then wreaking changes that
lead to mood disorders;
• cause the brain to develop in a way that directly fos-
ters both types of disorder, for example through vul-
nerability to neuronal sensitization and kindling.
Diagnostic Confounding
Some portion of the reported high co-occurrence of
SUD and mood disorders may represent confound-
ing of mood disorders and transient symptoms related
to acute abuse and withdrawal. Drug abuse symptoms
can mimic symptoms of both depression and mania.
Acute alcohol and stimulant intoxication can produce
symptoms of mania or hypomania, and substance
withdrawal often manifests as symptoms of dyspho-
ria and depression. Chronic use of central nervous sys-
tem (CNS) stimulants, such as cocaine and amphet-
amines, may produce symptoms that are typical of
bipolar spectrum disorders, such as euphoria, increased
energy, decreased appetite, grandiosity, and paranoia.
Conversely, withdrawal from CNS stimulants (espe-
cially cocaine) can give rise to anhedonia (inability to
feel pleasure), apathy, depressed mood, and suicidal
* Manic episode: abnormally elevated/expansive/irritable mood for at least 1 week.
**Mixed episode: meets criteria for manic and depressed episode daily for 1 week.
***Hypomanic episode: elevated/expansive/irritable mood for at least 4 days—little functional   
impairment.
TABLE 1. DSM-IV MOOD DISORDER CATEGORIZATION
Some gene
variants may
contribute to
risk for both
substance
abuse and
mood 
disorders.
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ideation. Chronic use of CNS depressants (e.g., alco-
hol, benzodiazepines, barbiturates, and opiates) can
lead to depressive symptoms such as poor concen-
tration, anhedonia, and problems sleeping, while with-
drawal from these drugs can result in anxiety and agi-
tation. The more subtle affective disorders such as
dysthymia and cyclothymia are particularly difficult
to differentiate from symptoms of SUD.
It remains unclear which, if any, of the models
discussed explain the high comorbidity between mood
disorders and SUDs. The relationship is complex and
bidirectional, suggesting an ongoing interaction between
these disorders; having one may affect the vulnera-
bility to developing the second or change its clinical
course.
ASSESSMENT AND DIAGNOSIS
A substance-abusing patient who exhibits symptoms
of a mood disorder may be suffering from acute intox-
ication or withdrawal, substance-induced mood dis-
order, preexisting affective disorder, or a combination
of these conditions. The potential for diagnostic uncer-
tainty and confusion is high, but a methodical approach
can point clinicians in the right direction.
One good strategy for busy treatment settings is
to screen patients upon intake to identify those whose
affective status warrants more careful assessment
and followup. The Symptom Checklist (SCL-90) is a
widely used instrument that has reasonable validity in
detecting general distress as an indicator of psychiatric
illness, but does not provide information about spe-
cific psychiatric diagnoses. The SCL-90 has high sen-
sitivity and moderate specificity for anxiety and mood
disorders in substance abuse patients, which are good
characteristics for a screen: It will let few patients with
these problems slip by, while false positives will be
identified at the more thorough follow-up assessment.
The Addiction Severity Index (ASI) is sometimes used
in substance abuse treatment settings to guide treat-
ment planning. This instrument has a psychiatric sub-
scale score that detects general distress reasonably well.
In one study, this subscale score correlated with SCL-
90 scores in a group of substance-dependent women
(Comfort et al., 1999). The Beck Depression Inventory
(BDI) is another brief self-report instrument with
demonstrated utility in detecting depression in sub-
stance abuse treatment settings. 
Before attempting a definitive diagnostic assess-
ment, it is best to wait until the patient has had a rea-
sonable period of abstinence. Doing so gives symp-
toms of acute intoxication and withdrawal time to
subside. For example, a number of studies have found
a 30 to 50 percent decrease in depression rating scores
from the first day of abstinence to the end of the sec-
ond week (Goldsmith and Ries, 2003). The appro-
priate minimum abstinence interval varies, depend-
ing on both the diagnosis under consideration and
the substance of abuse. Long-acting drugs (e.g.,
diazepam, methadone) require longer abstinence prior
to diagnosis than do shorter acting compounds (e.g.,
alcohol, cocaine). For individuals on methadone, a
confident diagnosis can generally be made and treat-
ment initiated if mood symptoms persist after 4 weeks
on a stable maintenance dosage.
During abstinence pending diagnostic assess-
ment, patients with symptoms indicating possible
mood disorders generally need support and supervi-
sion. Some require observation in an inpatient set-
ting, either due to symptoms of withdrawal that require
treatment in a controlled environment or because
of psychiatric symptoms such as suicidality or mania.
When patients show severe symptoms of depression,
mania, or hypomania, immediate treatment rather
than continued waiting may be necessary to relieve
suffering and facilitate treatment engagement.
The symptoms and history should be weighed
carefully together in the diagnostic assessment. Guiding
principles are:
• If a patient’s symptoms seem typical of intoxication
or withdrawal from a drug the patient has been abus-
ing, especially with no previous psychiatric history,
that is probably all they are. Expect them to remit
soon, generally within days.
• Patients who have substance-induced mood dis-
orders exhibit symptoms that result directly from
the lingering physiological effects of the substance
of abuse. Their affective difficulties commence within
4 weeks of last exposure to the substance, but are
more severe and long-lasting than those normally
associated with intoxication or withdrawal.
• Patients with underlying preexisting mood disor-
ders may experience symptoms of varying type and
intensity at any time during withdrawal or treat-
ment. A strong family history of mood disorder
makes diagnosis of a primary mood disorder more
likely, as do a patient history showing onset of symp-
toms prior to substance abuse, severity of symptoms
exceeding that normally seen in intoxication and
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withdrawal, and sustained mood symptoms fol-
lowing lengthy abstinence. 
CLINICAL COURSE AND TREATMENT
Studies indicate that individuals with SUD and a
mood disorder have a more severe clinical course and
worse outcomes than individuals who have only one
or the other. Alcohol and drug abuse are associated
with mood destabilization in individuals with affec-
tive disorders (Markou, Kosten, and Koob, 1998).
Keller and colleagues (1986) found that among a
group of bipolar patients, those with alcohol depend-
ence recovered more slowly than those without. In
comparing the histories of individuals with bipolar
disorder, Sonne and colleagues (1994) found that
those who also were substance abusers had an earlier
age of onset of bipolar episodes, more frequent hos-
pitalizations, and more comorbid psychiatric disor-
ders. Hasin and colleagues (2002) studied the tim-
ing of depressive episodes relative to remission and
relapse to substance abuse. They found that current
substance-induced major depressive disorder (MDD),
a history of MDD prior to the onset of substance
dependence, or a depressive episode experienced dur-
ing a 4-week initial abstinence reduced the odds that
the patient would achieve 6 months of continuous
abstinence.
A tragic association between SUDs, mood dis-
orders, and suicide has long been recognized. The 
disinhibition and despair often associated with 
intoxication likely set the stage for impulsive and 
self-destructive acts. In one study, two-thirds of 
individuals who committed suicide had an SUD 
(Rich, Fowler, and Young, 1989). In comparing a
number of psychiatric diagnostic groups, Young
and colleagues (1994) found that individuals with
MDD co-occurring with alcohol and drug depend-
ence were at the highest risk for suicide.
In sum, substance abuse appears to have an adverse
impact on the course and prognosis of mood disor-
ders, leading to more frequent hospitalizations and
treatment-resistant symptoms. On the other hand,
some data indicate that alleviation of mood symp-
toms can improve substance-abuse-related outcomes.
In general, treatment efforts addressing mood
disorders and SUDs have developed in parallel.
Integration of services and effective treatment strate-
gies from both fields can optimize outcomes when
the two disorders converge.
Psychotherapeutic Treatment
Maximum use of behavioral approaches is the first
principle of treatment for patients with SUD and a
concurrent mood disorder. First, learning and gain-
ing self-confidence in one’s ability to self-regulate sub-
jective states can be extremely helpful in recovery from
both disorders. Second, learning strategies to self-
regulate mood symptoms may help patients to break
out of the mindset of using external agents to com-
bat intolerable subjective states. 
The behavioral strategies used for patients with
co-occurring disorders should include elements of
proven efficacy for each. Cognitive-behavioral ther-
apies (CBTs) are among the most effective psychosocial
treatments for affective disorders and also have demon-
strated efficacy in the treatment of SUDs. Several
recently published pilot studies have validated psy-
chotherapeutic strategies specifically designed for
individuals with co-occurring disorders. In a study of
depressed alcoholics who received standard alcohol
treatment plus either CBT for depression or relax-
ation training (control group), the CBT group showed
greater improvements in depressive symptoms dur-
ing treatment and also had better drinking outcomes
at 3- and 6-month followup visits (Brown et al., 1997).
Weiss and colleagues (2000) compared a manual-
based CBT group therapy with treatment as usual for
patients with SUD and bipolar disorder, and found
that CBT produced significantly better outcomes
in a number of domains. A large treatment-matching
study of alcohol-dependent individuals compared
three psychosocial interventions: 12-step facilitation,
CBT, and brief motivational therapy. The treatments
were equally effective overall; however, patients with
high psychopathology as assessed by the ASI had bet-
ter outcomes with CBT than with 12-step facilita-
tion (Project MATCH Research Group, 1997).
Active participation in Alcoholics Anonymous
(AA) or Narcotics Anonymous (NA) can greatly
enhance recovery. Clinicians should encourage patients
with co-occurring disorders to affiliate with 12-step
groups that give clear, positive messages about the use
of prescribed psychotropic medications. Recognition
of the prevalence of co-occurring disorders has led to
the establishment of a number of self-help groups for
dual-diagnosis patients modeled on AA and NA, such
as Double-Trouble and Dual Recovery Anonymous.
While this development holds promise, the efficacy
of these groups needs to be systematically explored.
A tragic associ-
ation between
substance
abuse, mood
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suicide has
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recognized.MOOD DISORDER
Depression
Bipolar Disorder
AGENTS USED
Serotonin Reuptake
Inhibitors 
Fluoxetine (Prozac)
Sertraline (Zoloft)
Paroxetine (Paxil)
Citalopram (Celexa)
Escitalopram(Lexapro)
Tricyclic
Antidepressants
Imipramine (Tofranil)
Nortriptyline    
(Pamelor)
Other
Venlafaxine (Effexor)
Bupropion 
(Wellbutrin)
Mood Stabilizers
Lithium (Eskalith)
Valproate (Depakote)
Lamotrigine (Lamictal)
Atypical
Antipsychotics
Olanzapine (Zyprexa)
Risperidone 
(Risperdal)
Typical Antipsychotics
Haloperidol (Haldol)
Benzodiazepines*
Clonazepam 
(Klonopin)
AGENTS TO AVOID
Monoamine
Oxidase Inhibitors
Tranylcypromine 
(Parnate)
Phenelzine (Nardil)
Benzodiazepines
Diazepam (Valium)
Alprazolam (Xanax)
Stimulants
Methylphenidate 
(Ritalin)
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the prevalence of co-occurring disorders, developing
strong collaborative relationships between addiction
treatment professionals and local physicians and 
mental health centers is critical for optimizing patient 
outcomes.
Medicating Depression 
As discussed, prudence usually dictates waiting to start
a patient with SUD on a medication for depressed
mood until after detoxification. Doing so avoids unnec-
essarily exposing the patient to the expense and risk
of medications when his or her symptoms may resolve
of themselves in days or weeks. As well, it removes the
possibility of confounding symptoms of withdrawal
with side effects of the antidepressant medication.
The most common symptoms of substance with-
drawal—anxiety, agitation, sedation, nausea, and
headache—are also potential side effects of the agents
commonly used to treat depression, such as the sero-
tonin reuptake inhibitors (SRIs; e.g., sertraline), ven-
lafaxine, and bupropion.  Nevertheless, if depression
is severe and shows little sign of remitting within the
first few days of abstinence, and if risk factors are pres-
ent to suggest that a mood disorder may underlie it
(e.g., a positive family history of MDD), early phar-
macotherapeutic intervention may be justified. Table
2 lists the medications most frequently used to treat
mood disorders, as well as medications that individ-
uals with SUDs should avoid. 
Recently, Nuñes and Levin (2004) presented a
systematic review and meta-analysis of studies of anti-
depressant medications in the treatment of co-
occurring depression and SUDs. While over 300 stud-
ies have explored this issue, only 14 were placebo-
controlled trials that included subjects meeting rec-
ognized diagnostic criteria for depression and SUD.
Of the 14, five used tricyclic antidepressants (TCAs),
seven used SRIs, and two used other types of anti-
depressant agents. The results varied widely, with eight
studies reporting significant or trend antidepressant
effects and the rest finding none. Overall, the authors
concluded that antidepressant medications demon-
strated a modest beneficial effect for patients with
combined depression and SUD. The finding of 
efficacy was more robust for studies of alcohol-
dependent individuals than of drug-dependent indi-
viduals. Among the studies that demonstrated a decrease
in depression, medication also had a favorable effect
on substance abuse.
Pharmacotherapy
The past 10 years have seen an explosion of new psy-
chotherapeutic medications with enhanced efficacy
and tolerability. Treatment options have increased for
individuals with SUDs and those with mood disor-
ders, yet few studies have evaluated the new agents in
individuals who have both concurrently.
Even when community programs diagnose or
suspect mood disorders, they often lack clinicians who
can prescribe medications on site. In one recent study,
McLellan and colleagues (2003) found that fewer than
half of the Nation’s drug and alcohol treatment pro-
grams had a full-time physician or nurse. Considering
* Long-term use of benzodiazepines should be avoided.
TABLE 2. MEDICATIONS USED FOR THE TREATMENT OF
MOOD DISORDERS IN SUBSTANCE ABUSERS
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Nuñes and Levin also found that studies using
TCAs yielded more positive results than those using
SRIs, although they noted that this finding must be
interpreted with caution since:
• the negative SRI studies had high placebo response
rates, and
• the SRI studies that were positive demonstrated sub-
stantial medication effects on both depression
and substance abuse.
In their final analysis, the authors concluded
that SRIs should be the first-line medications for
depression when SUD is also present based on their
favorable tolerability and low toxicity compared to
the TCAs. Other new classes of antidepressant drugs,
like venlafaxine and bupropion, have shown promise
in pilot studies with individuals with comorbid depres-
sion and SUDs and warrant further investigation.
While antidepressant medications may be use-
ful, interventions to promote recovery from addic-
tions and stabilize the environment are essential parts
of successful treatment. A recent study starkly demon-
strated this point:  In a controlled trial with depressed
individuals in methadone maintenance for opioid
addiction, sertraline demonstrated significant effects
in ameliorating depression and decreasing drug use
only in those subjects who had more positive envi-
ronments—i.e., more social and familial contact, bet-
ter employment and monetary resources, and fewer
legal problems and interpersonal conflicts (Carpenter
et al., 2004).
Medicating Bipolar Disorder
While individuals with bipolar I disorder often receive
treatment in mental health rather than addiction set-
tings, the more subtle forms of bipolar disorder (bipo-
lar spectrum disorders: bipolar II, cyclothymia) are
more common than previously appreciated (Hirschfeld
et al., 2003). Compared with bipolar I disorder, bipo-
lar spectrum disorders are more difficult to distin-
guish from substance-induced mood symptoms and
may be more likely to present in the addiction treat-
ment setting. As with depression, the most accurate
diagnostic assessment can be made after a period of
abstinence. For bipolar patients in particular, a
close working relationship with mental health care
providers and/or psychiatric consultants will be essen-
tial to providing optimal care.
Despite the relatively frequent co-occurrence of
SUD and bipolar disorder, few studies have focused
on pharmacological therapy for patients with this dual
diagnosis. Several small pilot studies have shown that
patients with bipolar-SUD comorbidity benefit from
valproate and tolerate it well (Albanese, Clodfelter,
and Khantzian, 2000; Brady et al., 1995; Hertzman,
2000). In one such study, this population tolerated
and adhered to valproate better than to lithium 
(Weiss et al., 1998). A recent double-blind placebo-
controlled trial examining actively drinking bipolar
individuals treated with valproate versus placebo, with
both groups also receiving lithium and psychosocial
intervention, documented lower alcohol consump-
tion with valproate (LeFauve et al., 2004). While val-
proate did not produce superior mood outcomes,
there was a trend for individuals receiving it to remit
from mania sooner. A recent open-label trial by the
same investigators found that valproate plus naltrex-
one outperformed valproate alone in reducing sub-
stance abuse (0 percent versus 75 percent relapse rate)
as well as mood symptoms (Salloum, Cornelius, and
Chakravorthy, 2003). Additionally, carbamazepine
has been shown in one study to reduce cocaine abuse
in persons with cocaine dependence and affective dis-
order (Brady et al., 2002).
Individuals who have bipolar disorder compli-
cated by SUD are more likely to experience mixed
episodes of depression and mania and rapid cycling
between the two (Sonne and Brady, 1999). In patients
with uncomplicated bipolar disorder, both charac-
teristics predict a better response to anticonvulsant
mood-stabilizing agents (e.g., valproate, carbama-
zepine, lamotrigine) than to lithium (Swann et al.,
1999, 2002). Accordingly, some specialists have
hypothesized that substance-abusing bipolar patients
should receive an anticonvulsant rather than lithium
as a first-line therapy. This may be a reasonable approach,
but lithium can also be effective: A small placebo-
controlled trial with 25 adolescents with bipolar dis-
order and SUDs yielded significant associations between
lithium therapy, reduced drug abuse, and improved
mood symptoms (Geller et al., 1998).
With respect to other medications used to treat
bipolar disorder, no controlled studies to date have
evaluated the use of olanzapine in patients with 
bipolar-SUD comorbidity. In one reported case involv-
ing three patients, olanzapine reduced substance abuse,
cravings, and anxiety (Sattar et al., 2003). In a recently
conducted open-label trial, lamotrigine treatment
brought improvement in bipolar symptoms and
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decreased cocaine craving, but did not have a signif-
icant effect on drug abuse (Brown et al., 2003). Although
the pharmacotherapeutic treatment of comorbid bipo-
lar disorder and SUDs clearly needs further elucida-
tion, research has opened a number of promising
avenues for development.
CONCLUSIONS
Co-occurrence of SUD and affective disorders is com-
mon and has an impact on prognosis and treatment.
Diagnosis and assessment of these comorbid disorders
are difficult because of the substantial overlap in the
symptoms of substance intoxication, withdrawal, and
mood disorders. Using screening instruments to iden-
tify individuals with possible mood disorders and fol-
lowing up after a period of abstinence may be a par-
ticularly useful approach for busy clinicians.
Several treatment approaches have been devel-
oped specifically for patients with SUD and depres-
sion or bipolar disorder, and manuals for these 
approaches are available. While the use of complex
manual-guided therapies may not be practical in some
community treatment settings, these studies and 
others now under way should establish the critical
components and techniques of effective treatment 
for these patients. The best approach to implement-
ing these treatments in practice is an area that requires
further exploration.
Recent advances in the pharmacotherapy of mood
disorders benefit the population with co-occurring
disorders because the newer agents have less toxicity,
fewer side effects, and fewer interactions with sub-
stances of abuse. While few studies have specifically
evaluated pharmacotherapy in dual-diagnosis patients,
the results to date indicate that similar medications
are effective for mood disorders, whether or not SUD
also is present. Moreover, treatment of mood disor-
ders may be associated with decreased substance abuse.
Clearly, specific considerations in choosing a phar-
macologic agent for use in patients with SUD include
safety, toxicity, and abuse liability. 
While recent advances have identified specific
therapeutic options for individuals with co-occurring
SUDs and mood disorders, circumstances in both the
mental health and addiction treatment systems make
the delivery of optimal care difficult. In a recent study
of the national addiction treatment infrastructure,
McLellan and colleagues (2003) found that staff
turnover was high, fewer than one-half of programs
had a full-time nurse or physician, and very few pro-
grams had a social worker or psychologist. Given these
constraints, expanding communication and collabo-
ration between agencies and health care providers is
vital to providing optimal care for patients with co-
occurring disorders.
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